When, which and how to switch: Navigating JAK inhibitors in myelofibrosis.

IF 5.1 2区医学 Q1 HEMATOLOGY

British Journal of Haematology Pub Date : 2024-11-27 DOI:10.1111/bjh.19929

Jennifer O'Sullivan, Imran Omerdeen, Bethan Psaila

引用次数: 0

Abstract

Navigating choice of JAK inhibitor (JAKi) therapy for patients with myelofibrosis who are JAKi-naïve and for those who have previously been treated with a JAKi.

查看原文本刊更多论文

何时换药、换哪种药以及如何换药：为骨髓纤维化中的 JAK 抑制剂导航。

指导未接受过 JAKi 治疗的骨髓纤维化患者和曾接受过 JAKi 治疗的患者选择 JAK 抑制剂 (JAKi) 疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British Journal of Haematology 医学-血液学

CiteScore

8.60

自引率

4.60%

发文量

565

审稿时长

1 months

期刊介绍： The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.